| Literature DB >> 28807575 |
Suresh Paudel1, Xiao Min1, Srijan Acharya1, Daulat Bikram Khadka1, Goo Yoon2, Kyeong-Man Kim3, Seung Hoon Cheon4.
Abstract
Monoamine transporters are important targets in the treatment of various central nervous disorders. Several limitations of traditional reuptake inhibitors, like delayed onset of action, insomnia, and sexual dysfunction, have compelled the search for safer, more effective compounds. In this study, we have sought to identify novel monoamine reuptake inhibitors. Based upon the docking study of compounds that we had reported previously, aromatic rings (A1) were modified to generate a novel series of benzylpiperidine-tetrazoles. Thirty-one compounds were synthesized and evaluated for their triple reuptake inhibition of serotonin, norepinephrine and dopamine. Triple reuptake inhibitor, compound 2q, in particular, showed potent serotonin reuptake inhibition, validating our design approach.Entities:
Keywords: Benzylpiperidine–tetrazoles; Docking; Monoamine neurotransmitters; Norepinephrine and dopamine reuptake inhibitors; Serotonin
Mesh:
Substances:
Year: 2017 PMID: 28807575 DOI: 10.1016/j.bmc.2017.07.046
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641